In a major boost to India’s pharmaceutical credibility, global pharma major Lupin Limited announced that its Bioresearch Centre in Pune has successfully cleared a clinical inspection by the United States Food and Drug Administration (U.S. FDA) with zero Form 483 observations—a significant indicator of full compliance with regulatory standards.

The onsite inspection was conducted from November 3 to November 6, 2025, while a separate bio-analytical Remote Regulatory Assessment took place from October 30 to November 7, 2025. Both assessments concluded without any observations, underscoring the company’s robust quality systems and adherence to international best practices.

Expressing pride over the achievement, Nilesh Gupta, Managing Director, Lupin Limited, said, “The successful outcome of the onsite clinical inspection and bio-analytical assessment by the U.S. FDA at our Bioresearch Centre is testament to our ongoing commitment to quality and compliance. We remain focused on improving the lives of our patients globally.”

The U.S. FDA’s clean report reinforces Lupin’s reputation as a trusted global pharmaceutical player and reflects India’s growing role in maintaining world-class research and regulatory standards in drug development.